Colon Cancer Clinical Trial
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
All comers solid tumor subjects with histologically confirmed advanced or metastatic disease who have relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
Adult patients aged >/=18 years, able to provide informed consent and willing to comply with all study procedures.
Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
Adequate bone marrow, liver, and renal functions.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Subjects who have new or progressive brain or meningeal or spinal metastases.
Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.
Major surgery or significant trauma within 4 weeks before the first dose of study drug.
Medical history of chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Austin Texas, 78758, United States More Info
San Antonio Texas, 78229, United States More Info
Brisbane Queensland, 4101, Australia More Info
Adelaide Southern Australia, 5037, Australia More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.